-
Sanofi, Regeneron Report Positive Phase 3 Results For Asthma Drug Dupixent's Use In Children
Tuesday, October 13, 2020 - 5:46am | 418Read More...Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) disclosed that their asthma drug Dupixent (dupilumab) met its primary and all key secondary endpoints in randomized Phase 3 clinical trials demonstrating improved lung functions in children aged between six to 11 years. Data...
-
Spectrum Pharmaceuticals Shares Up 5% Following FDA Accelerated Approval For Beleodaq (SPPI)
Thursday, July 3, 2014 - 11:46am | 275Read More...Shares of Spectrum Pharmaceuticals (NASDAQ: SPPI) gained 5.7 percent following the U.S. Food and Drug Administration's approval of the New Drug Application (NDA) for Beleodaq. Accelerated Approval for Beleodaq In an 8-K filing on Wednesday, Spectrum reported that it gained accelerated...
